Premium
GINS2 facilitates epithelial‐to‐mesenchymal transition in non‐small‐cell lung cancer through modulating PI3K/Akt and MEK/ERK signaling
Author(s) -
Liu Xiangli,
Sun Lei,
Zhang Song,
Zhang Shuguang,
Li Wenya
Publication year - 2020
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.29381
Subject(s) - protein kinase b , pi3k/akt/mtor pathway , mapk/erk pathway , epithelial–mesenchymal transition , cancer research , cell growth , cell migration , biology , viability assay , kinase , metastasis , cell , signal transduction , cancer , microbiology and biotechnology , biochemistry , genetics
Abstract Non‐small‐cell lung cancer (NSCLC) is a cancer with high morbidity and mortality. We aimed to define the effect of Go‐Ichi‐Ni‐San complex subuint 2 (GINS2) acting on NSCLC. The expressions of GINS2 in NSCLC tissues and cells were detected using real‐time quantitative polymerase chain reaction, western blot, and immunohistochemistry (IHC). The relationship between GINS2 expression and NSCLC prognosis or clinicopathologic features was analyzed through statistical analysis. The overexpressed or downexpressed plasmids of GINS2 were transfected into NSCLC cell lines, and then cell proliferation, invasion, and migration viability were, respectively, determined by Cell Counting Kit‐8 assay, transwell, and wound healing assay. The epithelial–mesenchymal transition (EMT) was observed and the EMT‐related proteins were measured using IHC and western blot. The function of GINS2 in vivo was assessed by mice model. The related proteins of mitogen‐activated protein kinase (MEK)/extracellular signal‐regulated kinase (ERK) and phosphoinositide‐3‐kinase/protein kinase B (PI3K/Akt) pathways were evaluated using western blot. GINS2 expression was upregulated in NSCLC tissues and cell lines, and its high expression was correlated with the poor prognosis and several clinicopathologic features, such as TMN stages (tumor size, lymph node, and metastasis) and clinical stages. GINS2 enhanced NSCLC cell proliferation, migration, and invasion viability in vivo and in vitro. GINS2 also promoted NSCLC cells EMT. In addition, GINS2 could regulate phosphorylated proteins of PI3K p85, Akt, MEK, and ERK expressions, it revealed that GINS2 effected on PI3K/Akt and MEK/ERK pathways. GINS2 promoted cell proliferation, migration, invasion, and EMT via modulating PI3K/Akt and MEK/ERK signaling pathways. It might be a target in NSCLC treatment.